COVID-19 Vaccine (Covaxin)

Covaxin (BBV152) is India's first indigenously developed COVID-19 vaccine by Bharat Biotech International using whole-virion inactivated SARS-CoV-2 technology with Alhydroxiquim-II adjuvant. It received Emergency Use Authorization from DCGI in January 2021. It is a WHO-prequalified vaccine used globally.

The COVID-19 Vaccine (Covaxin) is recommended for 6 months+ (children: 2-18 years with authorization). It falls under the COVID-19 vaccine category. Consult your doctor to confirm if this vaccine is right for you based on your health history and existing immunity.

The COVID-19 Vaccine (Covaxin) has an efficacy of 77.8% against symptomatic COVID-19 in Phase 3 trials; >90% against severe disease. This means it provides significant protection against COVID-19 disease (caused by SARS-CoV-2) and Severe COVID-19. Efficacy may vary based on age, health status, and the specific strain encountered.

Common side effects include: Injection site pain; swelling; tenderness (common); fatigue. These are typically mild and resolve within 1–3 days. Serious allergic reactions are rare — if you experience difficulty breathing, hives, or rapid heartbeat after vaccination, seek emergency care immediately.

The COVID-19 Vaccine (Covaxin) should be avoided by: Known allergy to vaccine components (including alum adjuvant); immune-mediated disorders; thrombocytopenia. Defer in acute COVID-19 infection until recovered and 3 months have passed.. Always inform your healthcare provider of your full medical history before vaccination.

The COVID-19 Vaccine (Covaxin) typically costs ₹1,200 (private) / Free (Govt) in India. Government health centres may offer it free or at subsidised prices for eligible age groups. Private hospitals and clinics may charge differently. Additional fees may apply for administration.